• Portfolio and commercial execution showing early signs of improvement
• Operational simplification and efficiency initiatives underway
• Transformation program progressing as planned

CSL Limited today provides an update on its FY26 outlook, additional pre-tax asset impairments and the progress of strategic initiatives to drive the company's next phase of growth. Interim CEO Gordon Naylor says the company's growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise, leading to a revision of the FY26 guidance. CSL now expects FY26 revenue to be around $15.2 billion and NPATA (excluding restructuring costs and impairments) to be around $3.1 billion, both on a constant currency basis. The key changes are related to U.S. Immunoglobulin, Albumin in China, and other factors. CSL continues to expect revenue growth in the second half of FY26 for CSL Behring, supported by underlying demand, ongoing commercial execution and benefits from operational and transformation initiatives. CSL also expects to recognise approximately $5 billion of non-cash, pre-tax impairments across FY26 and FY27, primarily related to CSL Vifor intangible assets and under-utilised property, plant and equipment. The global search for the next CEO is progressing, and Gordon Naylor will remain on the CSL Board as a Non-executive Director following the appointment and transition of the new CEO. Andy Schmeltz, Chief Commercial Officer, has decided to retire, and Diego Sacristan will assume the role effective July 1, 2026.

CSL now expects FY26 revenue to be around $15.2 billion and NPATA (excluding restructuring costs and impairments) to be around $3.1 billion, both on a constant currency basis.